Records containing: Overweight

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

• CLINICAL_TRIALS study record update · 2026-03-18
  Pilot Trial of the Move Healthier Group
• CLINICAL_TRIALS study record update · 2026-03-18
  A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SA030 Injection in Overweight or Obese Participants
• CLINICAL_TRIALS study record update · 2026-03-18
  A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
• CLINICAL_TRIALS study record update · 2026-03-17
  A Randomised, Placebo Controlled, Double Blinded Study Assessing the Safety, Tolerability and Pharmacokinetics of Single and Multiple Subcutaneous Doses of NNC0638-0355 in Participants With Overweight or Obesity
• CLINICAL_TRIALS study record update · 2026-03-17
  Bioequivalence of Two Survodutide (BI 456906) Formulations Via Subcutaneous Administration After Multiple Doses (an Open-label, Randomised, Multiple-dose, Crossover Trial)
• Organize your saved records without ads with Plus.
• CLINICAL_TRIALS study record update · 2026-03-17
  Cross-Sectional and Longitudinal Studies of 'Pre-Diabetes'
• CLINICAL_TRIALS study record update · 2026-03-13
  An Open-label, Non-randomised, Fixed-sequence, Two Period, Phase I Trial to Evaluate the Effect of Different Doses of BI 456906 (Survodutide) on the Single Dose Pharmacokinetics of Bupropion, Caffeine and Midazolam on Otherwise Healthy Volunteers With Overweight or Obesity
• CLINICAL_TRIALS study record update · 2026-03-13
  A Double-blind, Randomized, Placebo-controlled, Multiple-dose, Parallel Group With Nested Crossover Design Trial With Moxifloxacin as Positive Control to Evaluate the Effects of Multiple Subcutaneous Doses of BI 456906 in a Titration Scheme on Cardiac Safety Parameters in (Otherwise) Healthy Male and Female Subjects With Overweight/Obesity
• CLINICAL_TRIALS study record update · 2026-03-13
  A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of IBI362 in Participants With Mild to Moderate Hypertension Complicated by Overweight/Obesity Who Have Not Received Antihypertensive Drug Treatment
• CLINICAL_TRIALS study record update · 2026-03-12
  A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic (PK) of Single-dose Administration of Semaglutide Nasal Spray (WL1006) in Adult Overweight or Obese Participants
• CLINICAL_TRIALS study record update · 2026-03-12
  Efficacy and Safety of NNC0487-0111 s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 8)
• CLINICAL_TRIALS study record update · 2026-03-09
  Pilot Tests to Optimize the Delivery of Energy Balance Interventions
• CLINICAL_TRIALS study record update · 2026-03-09
  A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy
• CLINICAL_TRIALS study record update · 2026-03-05
  A Phase-1, Parallel-Design, Open-Label, Randomized, Multiple-Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3549492 in Healthy Participants With Overweight or Obesity
• CLINICAL_TRIALS study record update · 2026-03-03
  Enhancing Weight Loss in a Digital Intervention Among Adults With Overweight or Obesity
• CLINICAL_TRIALS study record update · 2026-03-03
  Effect of a Structured Clinical and Pharmacological Management Strategy on Cardiovascular Risk Factors in Adult Patients in Routine Clinical Practice: A Pseudo-Experimental Before-and-After Study
• CLINICAL_TRIALS study record update · 2026-03-02
  A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
• CLINICAL_TRIALS study record update · 2026-03-02
  A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes
• CLINICAL_TRIALS study record update · 2026-02-27
  A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE DOSE, PARALLEL GROUP STUDY TO ASSESS RELATIVE BIOAVAILABILITY OF PF-08653944 WHEN ADMINISTERED ACROSS DIFFERENT INJECTION SITES IN ADULTS WITH OVERWEIGHT OR OBESITY
• CLINICAL_TRIALS study record update · 2026-02-27
  A First Human Dose Study Investigating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Single and Multiple Ascending Doses of NNC6989-0001 in Healthy Participants With Overweight or Obesity
• CLINICAL_TRIALS study record update · 2026-02-25
  A Placebo-controlled Comparability Study to Compare Two Presentations of CagriSema in Participants With Overweight or Obesity
• CLINICAL_TRIALS study record update · 2026-02-25
  Efficacy and Safety of Oral Semaglutide 25 mg Once Daily in Adults With Overweight or Obesity
• CLINICAL_TRIALS study record update · 2026-02-25
  A Phase 1, Double-blind, Two-arm, Mechanism of Action Study to Investigate the Effect of Orforglipron on Body Composition in Adult Participants With Obesity or Overweight, Without Diabetes
• CLINICAL_TRIALS study record update · 2026-02-19
  Evaluation of the Effects of Extra Virgin Olive Oil Consumption on Hepatic Steatosis Parameters and on Glucose and Lipid Metabolism in Subjects With MASLD.
• CLINICAL_TRIALS study record update · 2026-02-19
  010 Fit'R 2025-2027: Approach for Children (4-12 Years Old) With Overweight